Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the marketing of a Class 1 new drug independently developed by the company.

Rifusibizumab injection is an angiopoietin-like protein 3 (ANGPTL3) monoclonal antibody independently developed by the company. By inhibiting the activity of ANGPTL3, it reduces triglyceride (TG) and LDLC levels in serum. The approval was based on a randomized, double-blind, placebo-controlled phase III clinical study (SHR-1918-301) in HoFH patients aged 12 years or older. The findings were presented at the 2026 European Society of Cardiology (ESC) Annual Meeting LBA (Latest Breakthrough Scientific Report).

Currently, EVKEEZA® (evinacumab-dgnb), a same-targeted drug from regenerative companies abroad has been approved for marketing. According to the EvaluatePharma database, the product had global sales of approximately $216 million in 2025. Up to now, the total R&D investment for rifusibizumab injection-related projects is about RMB 302.9 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.